Abstract: Compositions useful as poliovirus immunogens are provided along with methods and compositions for preparing the same. Compositions comprising poliovirus immunogens can enable a host response that includes virus-neutralizing antibodies which can protect the host from infection and/or disease.
Type:
Grant
Filed:
March 29, 2019
Date of Patent:
July 23, 2024
Assignees:
BIOLOGICAL MIMETICS, INC., THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC
Abstract: A gene-modified coxsackievirus that is to be used in oncolytic virotherapy and is improved in safety and/or aggressiveness is provided. A gene-modified coxsackievirus that contains a mutated genome with a coxsackievirus B3 wild-type (CVB3-WT) genome inserted with at least one polynucleotide constituted of a target sequence for at least one of either of miR-34a and miR-34c and is suppressed in proliferation in normal cells is provided.
Type:
Grant
Filed:
April 18, 2018
Date of Patent:
July 16, 2024
Assignees:
THE UNIVERSITY OF TOKYO, NPT CO., LTD.
Inventors:
Yang Jia, Shohei Miyamoto, Kenichiro Hara, Atsuhumi Iwanaga, Kenzaburo Tani
Abstract: Embodiments include therapeutic peptides for preventing or reducing the transmission of a coronavirus such as SARS-CoV2. Also included are methods of using therapeutic peptides for reducing or preventing transmission of a coronavirus such as SARS-CoV2. The therapeutic peptides can prevent a region of the surface glycoprotein “spike” on SARS-CoV2 from interacting with angiotensin converting enzyme-2 (ACE-2) of host cells.
Abstract: The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.
Type:
Grant
Filed:
September 25, 2023
Date of Patent:
July 9, 2024
Assignees:
Centre National de la Recherche Scientifique (CNRS), Université Paris-Saclay
Inventors:
Aurélie Albertini, Yves Gaudin, Hélène Raux, Laura Belot, Jovan Nikolic
Abstract: Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections.
Type:
Grant
Filed:
February 8, 2021
Date of Patent:
July 9, 2024
Assignee:
RNAimmune, Inc.
Inventors:
Shenggao Tang, Dong Shen, Chun Lu, Ziyang He, Jiaxi He, Patrick Y. Lu
Abstract: Disclosed is a vaccine containing an MTV transition protein. A further version of the invention is a vaccine comprising MTV polypeptides coupled to a carrier protein. MTV may be treated by providing an MTV vaccine with an MTV transition protein; and, administering said vaccine.
Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting a pig against Streptococcus suis, characterised in that the IgM protease antigen is a protein according to SEQ ID NO:1.
Type:
Grant
Filed:
November 22, 2019
Date of Patent:
July 2, 2024
Assignee:
Intervet Inc.
Inventors:
Theodora Johanna Van Kasteren-Westerneng, Antonius Arnoldus Christiaan Jacobs
Abstract: Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.
Type:
Grant
Filed:
March 28, 2019
Date of Patent:
June 25, 2024
Assignee:
ABELZETA INC.
Inventors:
Yi Hong, Ting Yan, Jiangguo Ying, Haojie Zhang, Li Zhang, Fei Wang, Dijun Zhao, Luyi Zhang
Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.
Type:
Grant
Filed:
January 31, 2023
Date of Patent:
June 25, 2024
Assignee:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Inventors:
Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
Abstract: Disclosed are methods of treating a patient exposed to MTV. Also disclosed is a purified cDNA encoding an MTV transition protein peptide chain. Also disclosed is a vaccine containing an MTV transition protein. A further version of the invention is a vaccine comprising MTV polypeptides coupled to a carrier protein. MTV may be treated by providing an MTV vaccine with an MTV transition protein; and, administering said vaccine. In further instances, the MTV vaccine is administered with an antiretroviral medication.
Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
Type:
Grant
Filed:
September 26, 2022
Date of Patent:
June 18, 2024
Assignee:
Valneva SE
Inventors:
Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenführ, Jürgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Porcine Epidemic Diarrhea Virus (“PEDV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine PEDV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length PEDV genomes that can replicate efficiently in host animals and tissue culture.
Type:
Grant
Filed:
September 15, 2020
Date of Patent:
June 11, 2024
Assignees:
Zoetis Services LLC, Iowa State University Research Foundation, Inc.
Inventors:
Jianqiang Zhang, Qi Chen, Phillip Gauger, Darin Madson, John Morgan Hardham, Meggan Bandrick, Jay Gregory Calvert, James Richard Thompson, Mira Ivanova Stoeva, Walter Valdez
Abstract: The present invention relates to African swine fever virus (ASFV) peptides and/or polypeptides as well as immunogenic fragments thereof, corresponding encoding AFSV oligonucleotides and/or polynucleotides as well as immunogenic fragments thereof, immunogenic compositions, vaccines and uses thereof.
Type:
Grant
Filed:
December 16, 2022
Date of Patent:
June 4, 2024
Inventors:
Veljko Nikolin, Egbert Siegfried Mundt, Fernando Rodriguez Gonzalez, Laia Bosch Camos, Javier Alonso Collado Miguens
Abstract: In some embodiments, the present invention provides respiratory syncytial virus (RSV) F proteins, polypeptides and protein complexes that comprise one or more cross-links to stabilize the protein, polypeptide or protein complex in its pre-fusion conformation. In some embodiments the present invention provides RSV F proteins, polypeptides and protein complexes comprising one or more mutations to facilitate such cross-linking. In some embodiments the present invention provides compositions comprising such proteins, polypeptides or protein complexes, including vaccine compositions, and methods of making and using the same.
Type:
Grant
Filed:
May 27, 2021
Date of Patent:
May 28, 2024
Inventors:
Christopher Patrick Marshall, Jason Scott McLellan, Peter Joseph Alff, Claudio Bertuccioli, Roberto Mariani
Abstract: Certain aspects of the present disclosure generally relate to systems and methods for determining viruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, the virus may partition into one or more phases. In some cases, a virus-binding moiety facilitates partitioning of the virus. The phases may be assayed to determine the virus based on, e.g., quantitative or qualitative assessments of the distribution of virus-binding and/or signaling moieties. The virus-binding moiety may be attached to particles that may form a complex around a virus. The complex may be detectable without a signaling moiety (e.g., as a color change) in some embodiments. In some cases, more than one virus may be determined. For example, a virus-binding moiety may substantially alter the partitioning behavior of one virus or complex, relative to another, by being selective for the first virus.
Abstract: Nucleic acids encoding norovirus VP1 fusion proteins and VLPs comprising the norovirus VP1 fusion proteins are provided. Methods for norovirus VP1 fusion protein and norovirus VLP production in plants are also described. The VP1 fusion protein comprises, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain.
Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
Type:
Grant
Filed:
September 11, 2023
Date of Patent:
May 14, 2024
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
Abstract: The present invention in particular relates to a method of producing an immunogenic composition exhibiting reduced virucidal activity, as well as to the immunogenic composition and uses thereof, wherein the method in particular comprises the steps of: (a) providing a mixture with a first liquid and a recombinant protein, (b) concentrating the recombinant protein in the mixture by removing a portion of the first liquid from the mixture, and (c) processing the solution resulting from step (b) by continuous diafiltration.
Type:
Grant
Filed:
March 25, 2019
Date of Patent:
April 16, 2024
Inventors:
Leigh Wilmes, Matthew Coons, Amanda Brown, Michael Johannes Gassel, Francois-Xavier Orveillon, Katharina Hedwig Toepfer, Elida Bautista, Kathy Schlesinger
Abstract: Disclosed herein are methods and systems for rapid detection of antibiotic resistance of a microorganism in a sample. A modified recombinant phage is also disclosed which comprises an indicator gene in the late gene region. The specificity of infectious agents allows a specific microorganism to be targeted, and an indicator signal may be amplified to optimize assay sensitivity.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
April 9, 2024
Assignee:
Laboratory Corporation of America Holdings
Inventors:
Minh Mindy Bao Nguyen, Dwight L. Anderson, Jose S. Gil, Stephen E. Erickson, Matthew J. Brown
Abstract: A method is described for producing a vaccine from a neutered pathogenic source. The neutered pathogenic source may be a SARS-COV-2 virus that is neutered with a defined dose of UV-C light. The neutered SARS-COV-2 viral vaccine is administered through an inhalation pump.